首页> 外文OA文献 >Vesicular Stomatitis Virus as a Vector To Deliver Virus-Like Particles of Human Norovirus: a New Vaccine Candidate against an Important Noncultivable Virus▿
【2h】

Vesicular Stomatitis Virus as a Vector To Deliver Virus-Like Particles of Human Norovirus: a New Vaccine Candidate against an Important Noncultivable Virus▿

机译:水泡性口炎病毒作为载体传递人诺如病毒的病毒样颗粒:针对重要不可培养病毒的新型疫苗候选者

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Human norovirus (HuNoV) is a major causative agent of food-borne gastroenteritis worldwide. Currently, there are no vaccines or effective therapeutic interventions for this virus. Development of an attenuated vaccine for HuNoV has been hampered by the inability to grow the virus in cell culture. Thus, a vector-based vaccine may be ideal. In this study, we constructed a recombinant vesicular stomatitis virus (rVSV-VP1) expressing VP1, the major capsid protein of HuNoV. Expression of the capsid protein by VSV resulted in the formation of HuNoV virus-like particles (VLPs) that are morphologically and antigenically similar to native virions. Recombinant rVSV-VP1 was attenuated in cultured mammalian cells as well as in mice. Mice inoculated with a single dose of rVSV-VP1 through intranasal and oral routes stimulated a significantly stronger humoral and cellular immune response than baculovirus-expressed VLP vaccination. Moreover, we demonstrated that mice inoculated with rVSV-VP1 triggered a comparable level of fecal and vaginal IgA antibody. Taken together, the VSV recombinant system not only provides a new approach to generate HuNoV VLPs in vitro but also a new avenue for the development of vectored vaccines against norovirus and other noncultivable viruses.
机译:人类诺如病毒(HuNoV)是全球食源性胃肠炎的主要病原体。当前,没有针对该病毒的疫苗或有效的治疗干预措施。 HuNoV减毒疫苗的开发因无法在细胞培养物中生长病毒而受到阻碍。因此,基于载体的疫苗可能是理想的。在这项研究中,我们构建了表达VP1(HuNoV的主要衣壳蛋白)的重组水泡性口炎病毒(rVSV-VP1)。 VSV衣壳蛋白的表达导致HuNoV病毒样颗粒(VLP)的形成,其形态和抗原学上均与天然病毒体相似。重组rVSV-VP1在培养的哺乳动物细胞和小鼠中减毒。与通过杆状病毒表达的VLP疫苗相比,通过鼻内和口服途径单次接种rVSV-VP1的小鼠刺激的体液和细胞免疫应答明显增强。此外,我们证明了接种rVSV-VP1的小鼠触发了相当水平的粪便和阴道IgA抗体。综上所述,VSV重组系统不仅为体外产生HuNoV VLP提供了一种新方法,而且为开发针对诺如病毒和其他不可培养病毒的载体疫苗提供了一条新途径。

著录项

  • 作者

    Ma, Yuanmei; Li, Jianrong;

  • 作者单位
  • 年度 2011
  • 总页数
  • 原文格式 PDF
  • 正文语种 en
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号